PMID- 21804104
OWN - NLM
STAT- MEDLINE
DCOM- 20120131
LR  - 20230808
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 32
IP  - 23
DP  - 2011 Dec
TI  - Characterization of dyspnoea in PLATO study patients treated with ticagrelor or 
      clopidogrel and its association with clinical outcomes.
PG  - 2945-53
LID - 10.1093/eurheartj/ehr231 [doi]
AB  - AIMS To describe the incidence of dyspnoea and its associations with demographic 
      characteristics and clinical outcomes in patients with acute coronary syndromes 
      (ACS) treated with ticagrelor or clopidogrel in the PLATelet inhibition and 
      patient Outcomes (PLATO) study. METHODS AND RESULTS In the PLATO study, 18 624 
      patients were randomized to receive either clopidogrel [300-600 mg loading dose 
      (LD), 75 mg daily] or ticagrelor (180 mg LD, 90 mg b.i.d.). The occurrence of 
      reported dyspnoea adverse events (AEs) was analysed in the 18 421 patients who 
      received at least one dose of study medication in relation to demographic 
      characteristics, clinical outcomes and other associations of patients with and 
      without dyspnoea. A total of 1339 ticagrelor-treated patients (14.5%) and 798 
      clopidogrel-treated patients (8.7%) had a dyspnoea AE following randomization, 
      with respectively 39 (0.4%) and 24 (0.3%) classified as severe in intensity. 
      Excluding dyspnoea AEs occurring after the secondary endpoint of myocardial 
      infarction (MI), the yearly rates of the efficacy endpoints in dyspnoea AE 
      patients in the ticagrelor and clopidogrel groups were: for the primary composite 
      of CV death, MI, and stroke, 8.8 and 10.4% (unadjusted P = 0.25; adjusted P = 
      0.54); for CV death, 3.1 and 4.8% (unadjusted P = 0.024; adjusted P = 0.18); and 
      for total death 3.7 and 6.2% (unadjusted P = 0.004; adjusted P = 0.06), 
      respectively. CONCLUSIONS Ticagrelor-related dyspnoea is usually mild or moderate 
      in intensity and does not appear to be associated with differences concerning any 
      efficacy or safety outcomes with ticagrelor compared with clopidogrel therapy in 
      ACS patients.
FAU - Storey, Robert F
AU  - Storey RF
AD  - Department of Cardiovascular Science, University of Sheffield, UK. 
      r.f.storey@sheffield.ac.uk
FAU - Becker, Richard C
AU  - Becker RC
FAU - Harrington, Robert A
AU  - Harrington RA
FAU - Husted, Steen
AU  - Husted S
FAU - James, Stefan K
AU  - James SK
FAU - Cools, Frank
AU  - Cools F
FAU - Steg, Philippe Gabriel
AU  - Steg PG
FAU - Khurmi, Nardev S
AU  - Khurmi NS
FAU - Emanuelsson, Hakan
AU  - Emanuelsson H
FAU - Cooper, Anna
AU  - Cooper A
FAU - Cairns, Richard
AU  - Cairns R
FAU - Cannon, Christopher P
AU  - Cannon CP
FAU - Wallentin, Lars
AU  - Wallentin L
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110730
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy
MH  - Adenosine/adverse effects/*analogs & derivatives
MH  - Aged
MH  - Clopidogrel
MH  - Double-Blind Method
MH  - Dyspnea/*chemically induced
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Purinergic P2Y Receptor Antagonists/*adverse effects
MH  - Ticagrelor
MH  - Ticlopidine/adverse effects/*analogs & derivatives
MH  - Treatment Outcome
EDAT- 2011/08/02 06:00
MHDA- 2012/02/01 06:00
CRDT- 2011/08/02 06:00
PHST- 2011/08/02 06:00 [entrez]
PHST- 2011/08/02 06:00 [pubmed]
PHST- 2012/02/01 06:00 [medline]
AID - ehr231 [pii]
AID - 10.1093/eurheartj/ehr231 [doi]
PST - ppublish
SO  - Eur Heart J. 2011 Dec;32(23):2945-53. doi: 10.1093/eurheartj/ehr231. Epub 2011 
      Jul 30.